← Back to Search

Virus Therapy

Group 3: PfSPZ 102400 sporozoites for Malaria

Phase 1
Waitlist Available
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial will test a new malaria vaccine on 28 healthy volunteers to see if it's safe and effective. They'll get doses of the vaccine and a malaria drug & be tested for infection 10 wks later.

Eligible Conditions
  • Malaria

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Active Control
Group I: Group 1: PfSPZ 51200 sporozoites/PlaceboActive Control3 Interventions
Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
Group II: Group 2: PfSPZ 102400 sporozoites/PlaceboActive Control3 Interventions
CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
Group III: Group 3: PfSPZ 102400 sporozoitesActive Control2 Interventions
CQ/PfSPZ Challenge 102400 sporozoites N=9

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,311 Previous Clinical Trials
5,546,594 Total Patients Enrolled
153 Trials studying Malaria
623,554 Patients Enrolled for Malaria
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top